About PhRMA
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $850 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.
Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.AmericasMedicines.com
www.Facebook.com/PhRMA
www.X.com/PhRMA
WASHINGTON, D.C. (May 4, 2022) – The Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Andrew Powaleny released the following statement after the House Committee on Energy and Commerce released their legislative text around reauthorization of the Prescription Drug User Fee Act and Biosimilar User Fee Act:
“Every five years, Congress plays a pivotal role in reauthorizing user fee agreements that are critical to the development of innovative medicines and biosimilar products. The release of the legislative text for this year’s reauthorization process marks an important step to ensure these programs continue – without interruption.
“As the legislation moves forward, it is important that the integrity of the reauthorization of these critical programs not be undermined by the inclusion of extraneous policies that would slow the reauthorization process and jeopardize the U.S. Food and Drug Administration’s (FDA) timely review and approval of critical new medicines.
“We urge lawmakers to move swiftly in reauthorizing these programs that were negotiated with the FDA. It is vital FDA’s workforce can continue to support patient safety, maintain high standards of independent regulatory review and promote timely access to safe and effective medicines for patients.”
Press Release
FDA
PhRMA Statement on User Fee Legislative Text
PhRMA Statement on User Fee Legislative Text image